Drug Trial Radar · NCT04586231
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
747
Actual
Start
Feb 25, 2021
Primary completion
Feb 2, 2026
Study completion Feb 11, 2027
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Eisai Inc.
- First posted
- Oct 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.
Conditions
- Carcinoma, Renal Cell
Interventions
BelzutifanDrug
Oral administration
LenvatinibDrug
Oral administration
CabozantinibDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 34 months
- Overall Survival (OS)Time frame: Up to approximately 44 months
Locations
184 sites in 25 countries. Site status is shown where the registry gives one.
Ironwood Cancer & Research Centers ( Site 0077)
Chandler, Arizona
Cedars Sinai Medical Center ( Site 0027)
Los Angeles, California
UCLA Hematology/Oncology - Santa Monica ( Site 0048)
Los Angeles, California
St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095)
Orange, California
University of California, Irvine ( Site 0029)
Orange, California
Providence Saint John's Health Center ( Site 0083)
Santa Monica, California
Georgetown University Medical Center ( Site 0006)
Washington D.C., District of Columbia
AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0003)
Orlando, Florida
Orlando Health, Inc. ( Site 0035)
Orlando, Florida
University Cancer & Blood Center, LLC ( Site 0057)
Athens, Georgia
Emory University Hospital ( Site 0012)
Atlanta, Georgia
Rush University Medical Center ( Site 0040)
Chicago, Illinois
Illinois Cancer Care, PC ( Site 0008)
Peoria, Illinois
Parkview Cancer Institute ( Site 0088)
Fort Wayne, Indiana
Norton Cancer Institute - St. Matthews ( Site 0065)
Louisville, Kentucky
Tulane University School of Medicine ( Site 0098)
New Orleans, Louisiana
Lahey Hospital & Medical Center ( Site 0090)
Burlington, Massachusetts
Cancer & Hematology Centers of Western Michigan ( Site 0018)
Grand Rapids, Michigan
HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005)
Saint Louis Park, Minnesota
University of Mississippi Medical Ctr ( Site 0037)
Jackson, Mississippi
Cancer Partners of Nebraska ( Site 0086)
Lincoln, Nebraska
Rutgers Cancer Institute of New Jersey ( Site 0078)
New Brunswick, New Jersey
R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0013)
Lake Success, New York
Memorial Sloan Kettering Cancer Center ( Site 0055)
New York, New York
Levine Cancer Institute ( Site 0004)
Charlotte, North Carolina
Duke Cancer Institute ( Site 0096)
Durham, North Carolina
Lehigh Valley Hospital- Cedar Crest-Oncology Clinical Trials ( Site 0056)
Allentown, Pennsylvania
University of Texas, Southwestern Medical Center ( Site 0015)
Dallas, Texas
Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 7001)
Salt Lake City, Utah
University of Vermont Medical Center ( Site 0001)
Burlington, Vermont
Blue Ridge Cancer Care - Roanoke ( Site 0043)
Roanoke, Virginia
Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 0093)
Seattle, Washington
Central Washington Health Services Association d/b/a Confluence Health ( Site 0061)
Wenatchee, Washington
Centro de Urología (CDU) ( Site 0803)
CABA, Buenos Aires, Argentina
Hospital Británico de Buenos Aires-Oncology ( Site 0801)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Instituto Alexander Fleming ( Site 0800)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Asociación de Beneficencia Hospital Sirio Libanés ( Site 0804)
Buenos Aires, Buenos Aires F.D., Argentina
Sanatorio Británico-Clinical Oncology Department ( Site 0802)
Rosario, Santa Fe Province, Argentina
Sanatorio Parque ( Site 0806)
Rosario, Santa Fe Province, Argentina
GenesisCare North Shore ( Site 4011)
St Leonards, New South Wales, Australia
Showing 40 of 184 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.